Clinical trial
Iressa v BSC (Best Supportive Care) in First Line NSCLC
NCT00259064 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00259064 |
|---|---|
| Title | Iressa v BSC (Best Supportive Care) in First Line NSCLC |
| Official title | A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor… |
| Acronym | INSTEP |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug, Other |
| Interventions | Gefitinib, Placebo |
| Enrollment | 216 |
| Start date | Sep 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Apr 1, 2016 |
| First posted | Nov 29, 2005 |
| Last update posted | Jun 2, 2016 |
| Countries | Australia, Canada, Czechia, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: